pone.0258437.g004.tif (181.49 kB)
Patients free from new/enlarged T2 lesions in the overall population and prior treatment subgroups.
figure
posted on 2021-10-13, 17:41 authored by J. E. Meca-Lallana, C. Oreja-Guevara, D. Muñoz, J. Olascoaga, A. Pato, L. Ramió-Torrentà, V. Meca-Lallana, M. A. Hernández, M. E. Marzo, J. C. Álvarez- Cermeño, A. Rodríguez-Antigüedad, X. Montalbán, O. FernándezAbbreviatures: BRACE: Betaseron (interferon beta-1b sc), Rebif (interferon beta-1a sc), Avonex (interferon beta-1a im), Copaxone (Glatiramer acetate), and Extavia (interferon beta-1b sc); EDSS, Expanded Disability Status Scale; IQR, interquartile range; N: Number of patients with available data for T2 Lesions; NTZ, natalizumab.
History
Usage metrics
Keywords
urinary tract infectionna &# 239multicenter case registrylesions progressively increasedenlarged t2 lesionsbrace ), natalizumabsix evaluable patientsadequate safety resultsmultiple sclerosis treatedmultiple sclerosisresults obtainedyear safetyyear 4xlink ">term usesignificant reductionradiological measurespreviously treatedpositive benefitpatients freeoverall populationmodifying therapyminimal deteriorationmean edssinterferon betaedss showededss scoresadverse events7 %]).5 %]5 %,43 centers4 years001 ).
